Results 91 to 100 of about 16,889 (275)

Effects of hydrogen gas inhalation on L-DOPA-induced dyskinesia

, 2023
L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia is a side effect of Parkinson's disease treatment and it is characterized by atypical involuntary movements.
Mariza Bortolanza, Danyelle Silva-Amaral, João F. Pedrazzi, Luiz G.S. Branco, Grant T. Harris, Elaine Del Bel, Glauce C. Nascimento, Bruna M. Santos   +7 more
core   +1 more source

Considerations for Initiation and Maintenance of Foslevodopa/Foscarbidopa for Advanced Parkinson's Disease

Movement Disorders Clinical Practice, EarlyView.
Abstract Background As Parkinson's disease (PD) progresses, motor fluctuations become increasingly difficult to manage with oral medications. Foslevodopa/foscarbidopa (LDp/CDp), delivered as a continuous 24‐h/day subcutaneous infusion, offers continuous levodopa delivery and stable plasma levodopa levels that reduce motor fluctuations. LDp/CDp has been
K. Ray Chaudhuri, Bruno Bergmans, Eric Freire‐Alvarez, Lucie Hopes, Drew S. Kern, Robert S. Kirsner, Giulia Lazzeri, Pedro Mendes‐Bastos, Noriko Nishikawa, Per Odin, Karolina Poplawska‐Domaszewicz, Rajesh Pahwa, Yuval Ramot, Klaus Seppi, Tobias Warnecke, Robert Wiggins, Megha B. Shah, Pavnit Kukreja, Bjoern Fritz, Koray Onuk, Stuart H. Isaacson   +20 more
wiley   +1 more source

MSBIS: A Multi-Step Biomedical Informatics Screening Approach for Identifying Medications that Mitigate the Risks of Metoclopramide-Induced Tardive Dyskinesia

EBioMedicine, 2017
In 2009 the U.S. Food and Drug Administration (FDA) placed a black box warning on metoclopramide (MCP) due to the increased risks and prevalence of tardive dyskinesia (TD). In this study, we developed a multi-step biomedical informatics screening (MSBIS)
Dong Xu, Alexandrea G. Ham, Rickey D. Tivis, Matthew L. Caylor, Aoxiang Tao, Steve T. Flynn, Peter J. Economen, Hung K. Dang, Royal W. Johnson, Vaughn L. Culbertson   +9 more
doaj   +1 more source

Levodopa-induced belly dancer's dyskinesia: Case report

Clinical Parkinsonism & Related Disorders, 2020
The first report of an abdominal wall dyskinesia syndrome was published in 1990 by Iliceto et al. (1990), who were the first to use the “belly dancer dyskinesia” (BDD) nomenclature. BDD is a rare syndrome involving repetitive, involuntary, and continuous
José Renan Miranda Cavalcante-Filho, Walterney Amâncio-Filho, Bruno Gonzales Miniello   +2 more
doaj   +1 more source

Ranitidine reduced levodopa-induced dyskinesia by remodeling neurochemical changes in hemiparkinsonian model of rats

, 2015
Hongjuan Shi,1,2,* Xinxin Yang,2,3,* Hui Zhao,4 Shenyang Zhang,2 Jie Zu,2 Wei Zhang,2 Xia Shen,2 Guiyun Cui,2,3 Fang Hua,2,3 Chuanzhu Yan1 1Department of Neurology, Qilu Hospital of Shangdong University, Jinan, 2Department of Neurology, Affiliated ...
Yang X, Zhang W, Hua F, Cui G, Yan C, Zhang S, Shen X, Shi H, Zhao H, Zu J   +9 more
core  

Dyskinesia Induced By Phenytoin.

, 2015
Phenytoin is an effective antiepileptic drug, although, it can be associated with many side effects, including dyskinesia. To describe the clinical characteristics of phenytoin induced dyskinesia.
Scotoni, A E, Montenegro, M A, Cendes, F
core  

Resolution of Levodopa/Dopa‐Decarboxylase Inhibitor—Associated Microscopic Colitis with Subcutaneous Foslevodopa/Foscarbidopa: A Case Series and Review of the Literature

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Microscopic colitis (MC) typically presents with chronic, non‐bloody watery diarrhea. Diagnosis requires endoscopy with colonic mucosal biopsies. The etiology is multifactorial, with several medications implicated, although only a few cases have been attributed to oral levodopa/dopa‐decarboxylase inhibitor (LDDCI) therapy.
Romana Hintner, Franziska Eberhardt, Manuela Kofler, Andreas Eigentler, Atbin Djamshidian, Florian Krismer, Anton Hittmair, Heinz Zoller, Valentina Ellinger, Beatrice Heim, Klaus Seppi   +10 more
wiley   +1 more source

Risk‐Benefit Considerations in Deep Brain Stimulation Discontinuation for Late‐Stage Parkinson's Disease

Movement Disorders Clinical Practice, EarlyView.
ABSTRACT Background Management of deep brain stimulation (DBS) in late‐stage Parkinson's disease (LSPD) remains challenging, particularly when deciding whether to continue or discontinue stimulation, and evidence on risk–benefit considerations is limited. Objectives To identify key factors to improve decision‐making in DBS management for LSPD patients.
Pietro Antenucci, Andrea Gozzi, Fabiana Colucci, Federica Pes, Jay Guido Capone, Alba Scerrati, Michele Alessandro Cavallo, Maura Pugliatti, Daniela Gragnaniello, Mariachiara Sensi   +9 more
wiley   +1 more source

Pallidal versus subthalamic nucleus deep brain stimulation for levodopa‐induced dyskinesia

Annals of Clinical and Translational Neurology, 2020
Objective To compare the efficacy of subthalamic nucleus (STN) and globus pallidus internus (GPi) deep brain stimulation (DBS) on reducing levodopa‐induced dyskinesia (LID) in Parkinson’s disease, and to explore the potential underlying mechanisms ...
Shi‐Ying Fan, Kai‐Liang Wang, Wei Hu, Robert S. Eisinger, Alexander Han, Chun‐Lei Han, Qiao Wang, Shimabukuro Michitomo, Jian‐Guo Zhang, Feng Wang, Adolfo Ramirez‐Zamora, Fan‐Gang Meng   +11 more
doaj   +1 more source

Exocrine Gland Dysfunction in Parkinson's Disease: Pathophysiology, Clinical Manifestations, and Therapeutic Perspectives—A Narrative Review

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Non‐motor symptoms, especially autonomic dysfunction, are major contributors to disability and decreased quality of life in Parkinson's disease (PD). Despite being common and having a wide range of clinical facets, exocrine gland dysfunction is still not well recognized and managed.
Renato P. Munhoz, Marina Farah, Laura Silveira‐Moriyama   +2 more
wiley   +1 more source